Jonathan Gamss, MD
Internal Medicine · Mount Kisco, NYNPI 1598922874
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 44.7% of the total. Reporting peaked in 2024 at $441 and has fallen 60.5% since, to $174 in 2025.
Across 68 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$677
- AstraZeneca$151
- Novo Nordisk$138
- Regeneron Healthcare Solutions, Inc.$125
- Johnson & Johnson$93
- Gilead$57
- plus $275 from 9 others
What the payments were for
- Food & beverage$1,515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $677 |
| AstraZeneca(2 entities) | 10 | $151 |
| Novo Nordisk | 2 | $138 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Johnson & Johnson | 6 | $93 |
| Gilead | 4 | $57 |
| CSL Behring | 2 | $49 |
| Pfizer | 3 | $48 |
| Boehringer Ingelheim | 3 | $40 |
| Meridian Bioscience Inc. | 1 | $38 |
| Vapotherm Inc | 1 | $30 |
| Bioxcel Therapeutics, Inc. | 1 | $22 |
| Inari Medical, Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,515 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $284 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $150 |
| Cefdinir | 11 | $129 |
| Metoprolol Succinate | 12 | $76 |
| Famotidine | 16 | $75 |
| Azithromycin | 11 | $28 |
| Losartan Potassium | 11 | $15 |
| Prednisone | 11 | $13 |
| Amlodipine Besylate | 13 | $13 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Mount Kisco
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.